Adare Pharma Solutions purchases Frontida BioPharm
Transaction expands CDMO’s services, including more solutions surrounding commercial manufacturing
Adare Pharma Solutions, a technology-driven contract development and manufacturing organization (CDMO), has acquired Frontida BioPharm, a vertically integrated CDMO that focuses on oral formulations. According to Adare, the deal helps offer solutions, from product development all the way through commercial scale manufacturing and packaging. The CDMO’s portfolio will expand to feature additional offerings, including high potency compound handling and packaging services.
Together, the combined company will provide additional solutions for complex oral formulations, such as taste masking, controlled release, high potency formulation manufacturing and bioavailability enhancement. The addition of Frontida brings Adare's manufacturing footprint to seven sites globally. The combined firm will be led by Vivek Sharma, who currently serves as Adare’s CEO.
"We are devoted to improving the quality of life for patients by solving the most complex formulation challenges for our customers, and we believe this acquisition will bolster our ability to achieve our mission,” says Sharma. “Frontida and Adare share a commitment to quality and innovation, and we are excited to continue growing together."
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
